Menu
No results found.
Weekly Share Price & Valuation Overview
Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer. It has a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutic. The company was founded in 2010 and is headquartered in Taipei City, Taiwan.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- TWD 4.91B
- Enterprise Value Operating value: market cap + total debt − cash.
- TWD 3.38B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- TWD 15.59M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- TWD 6.50M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- TWD 0.11
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.40
- Shares Outstanding
- 150.98M
- Float Shares
- 84.58M
- Implied Shares Outstanding
- 153.90M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-10.85%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
41.70%
- ROA Return on assets: net income ÷ total assets.
-
-5.94%
- ROE Return on equity: net income ÷ shareholder equity.
-
-4.74%
- Revenue Growth Year-over-year revenue growth.
-
-10.60%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 9.58
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.05
- Total Cash Cash and equivalents.
- TWD 1.56B
- Total Debt Short + long-term interest-bearing debt.
- TWD 81.59M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- TWD -1.48B
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- TWD -13.09M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-84.00%
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.